Whitehawk Therapeutics Highlights PTK7 as Key Cancer Target at AACR-NCI-EORTC Conference

Whitehawk Therapeutics Unveils Promising Findings on PTK7 as a Cancer Target

At the recent 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company, presents groundbreaking findings on the tumor marker Protein Tyrosine Kinase 7 (PTK7). In collaboration with Tempus AI, the company analyzes over 157,000 tumor samples to reveal that PTK7 is expressed in approximately 70% of solid tumors. This positions PTK7 as the third most highly expressed tumor marker among antibody-drug conjugate (ADC) targets, following HER2 and HER3, thus underscoring its potential significance in the field of oncology.

The analysis further uncovers that the median PTK7 mRNA expression is notably high in several cancer types, including endometrial (7.4), ovarian (7.2), head and neck (7.1), non-small cell lung cancer (NSCLC) (6.9), and breast tumors (6.7). Importantly, the expression of PTK7 remains stable across various histologic subtypes, disease stages, and metastatic statuses. This stability highlights PTK7’s potential as a pan-tumor target, which could pave the way for innovative treatment protocols that address multiple cancer types concurrently. Dr. Grace Dy emphasizes the translational potential of these findings, noting that the consistent expression of PTK7 across diverse solid tumors enhances its relevance for future therapeutic development.

In light of these promising results, Whitehawk's development of its PTK7-directed ADC candidate, HWK-007, gains renewed momentum. The comparative analysis indicates that PTK7 expression levels are comparable to established ADC targets like HER2 and Trop-2 across various cancer types. The absence of currently approved PTK7-directed ADCs signifies a substantial opportunity for Whitehawk to capitalize on the clinical relevance of PTK7. By further exploring this promising target, Whitehawk Therapeutics is poised to contribute significantly to the advancement of innovative cancer treatments.

In addition to the encouraging findings regarding PTK7, the data presented at the conference reflects Whitehawk's commitment to pioneering advancements in oncology therapeutics. The insights gained from the collaboration with Tempus AI not only bolster the company’s position in the industry but also highlight the increasing importance of precision medicine in cancer treatment. As Whitehawk continues to focus on the development of novel therapies, the implications of these findings could lead to enhanced patient outcomes and a paradigm shift in cancer care.